Evidence map›Paper›PMID 30374807›Full record

ReviewAdvances in therapy2018

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.

Jennifer Okemah, John Peng, Manuel Quiñones

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07394075 (Translating Continuous Glucose Monitoring), which is not on this map. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07394075 enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Translating Continuous Glucose Monitoring (CGM) Data Into Action to Improve Management of Insulin-Treated T2D in Primary Care

TypeobservationalSponsorHealthPartners InstituteRan2026 to 2028Enrolled150ConditionsType 2 DiabetesArmsContinuous Glucose Monitoring Clinical Decision Support
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Optimizing Type 2 Diabetes Management in Iraq: Expert Consensus on Initiation and Intensification of Insulin-Based Treatment Options.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Saudi family physician's clinical inertia of type 2 diabetes management.Journal of family medicine and primary care · 2026
    Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jennifer OkemahWestern Washington Medical Group, Diabetes and Nutrition Education, Bothell, WA, USA. jenoke@comcast.net.ORCID 0000-0003-1858-3040
John PengVirginia Mason Medical Center, Lynnwood, WA, USA.
Manuel QuiñonesHealthCare Partners, Anaheim, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current epidemic of type 2 diabetes (T2D) represents a significant global and national health concern. Globally, the prevalence of diabetes has doubled between 1980 and 2014. In 2014 the World Health Organization estimated that there were 422 million adults living with diabetes worldwide. In the USA, the number of people diagnosed with T2D is estimated to increase to over 70 million by 2050, putting an immense strain on the US healthcare system. Achieving glycemic control is widely acknowledged as the key goal of treatment in T2D and is critical for reducing the onset and progression of diabetes-related complications such as cardiovascular diseases, neuropathies, retinopathies, and nephropathies. Despite the increase in the availability of antihyperglycemic medications and evidence-based treatment guidelines, the proportion of people with T2D who fail to achieve glycemic goals continues to rise. One major contributor is a delay in treatment intensification despite suboptimal glycemic control, referred to as clinical or therapeutic inertia. Clinical inertia prolongs the duration of patients' hyperglycemia which subsequently puts them at increased risk of diabetes-associated complications and reduced life expectancy. Clinical inertia results from a complex interaction between patient, healthcare providers, and healthcare system barriers that need to be addressed together, rather than as separate entities. In this article we provide an overview of clinical inertia in the clinical management of T2D and provide suggestions for overcoming aspects that may have a negative impact on patient care.Funding: Sanofi US, Inc.

Indexed as

Early DiagnosisPractice Guidelines as TopicAdultAgedAged, 80 and overDiabetes Mellitus, Type 2FemaleHumansHyperglycemiaHypoglycemic AgentsMaleMiddle AgedTime-to-TreatmentUnited StatesHypoglycemic AgentsClinical inertiaTherapeutic inertiaTreatment intensificationType 2 diabetes

Identifiers

PMID30374807
PMCPMC6223992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.